CTOs on the Move

SIGA Technologies

www.siga.com

 
SIGA Technologies is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.siga.com
  • 35 E 62nd St
    New York, NY USA 10065
  • Phone: 212.672.9100

Executives

Name Title Contact Details

Similar Companies

ImClone Systems

ImClone Systems is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Kymanox

Kymanox is a professional services organization with a focus on project delivery. Our team of experts provide guide you and your project.

SeniorBridge Family

SeniorBridge Family is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Codagenix

Codagenix Inc. is a clinical stage biotechnology company with vaccine products against influenza, respiratory syncytial virus, dengue virus, and others currently under development. Codagenix uses a computer-based algorithm, called SAVE (Synthetic Attenuated Virus Engineering) to design viral genomes that are identical to the wild type strain at the amino acid level, but make less protein in human cells.

Fate Therapeutics

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company`s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Company`s immuno-regulatory product candidates include ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA.